#USA #Boston #Cell Therapy #AMD Ventures #Somite.ai

Somite.ai Secures Investment to Transform Cell Therapy

On August 20, 2025, Somite.ai, an innovative company at the forefront of developing foundation models for human stem cells, announced an exciting strategic investment from AMD Ventures. This collaboration follows Somite's impressive Series A funding round, which raised $47 million led by Khosla Ventures earlier in May. The partnership promises to integrate Somite's cutting-edge capsule-based data generation platform with AMD's advanced Instinct™ GPUs, which are known for their exceptional computational power.

Somite.ai is redefining the landscape of cell therapy by creating large-scale foundation models designed to expedite the development of new cell therapies significantly. The company's pioneering capsule technology can produce differentiation data at a fraction (1/1000th) of the cost compared to traditional methods. This groundbreaking approach unlocks capabilities for extensive scale and precision in training sophisticated predictive models, marking a substantial leap toward enhancing therapeutic interventions.

According to Dr. Micha Breakstone, the Co-Founder and CEO of Somite.ai, “We are on the cusp of a breakthrough in data generation focused on cell-state transitions. Our capsule-based platform generates dense, causal datasets crucial for training transformative foundation models. With AMD's support, we are confident in our potential to deliver impactful solutions.”

The implications of this partnership extend beyond mere computational enhancements. Sagi Paz, Head of AMD Ventures, shared insights into the nature of this collaboration, declaring, “Biology is undergoing a computational revolution similar to that seen in language and vision fields. Somite is at the helm of this evolution, and AMD Instinct GPUs are perfectly tailored to handle the demanding requirements of their ambitious models.”

The collaborative effort aims not only to optimize software tools designed for analyzing biological data but also to drive the development of specialized solutions that cater to next-generation foundation models. This strategic move underscores the increasing importance of artificial intelligence in the life sciences, highlighting the synergy between technological advancements and improved patient outcomes.

Somite.ai is committed to fostering a holistic approach to cell therapies, leveraging AI foundation models to achieve rapid scaling of these therapies. The company has an impressive founding team, which includes Dr. Micha Breakstone, who has previously built successful AI ventures, and leading experts in the field, including three members of the National Academy of Sciences. Since its inception, Somite has raised approximately $60 million, reflecting strong investor confidence in its innovative vision and business model.

With operations set to launch in January 2024 from its headquarters in Boston, Somite.ai is poised to make significant strides in the realm of cell therapies, potentially benefitting millions of patients globally. As it continues to refine and optimize its groundbreaking approaches, the intersection of AI and biology should yield transformative advancements in health care, ultimately changing the way therapies are developed and delivered to patients in need.

In summary, the strategic investment from AMD Ventures represents a milestone for Somite.ai, serving as a catalyst for faster advancements in the field of cell therapy that could revolutionize treatment paradigms. With both companies dedicated to pushing the boundaries of technology and medicine, the partnership foretells an era of accelerated innovation in therapeutic solutions.